Menu
← Oncology Approval Tracker
FDA DECISION ·
Tevimbra
tislelizumab-jsgr · BeOne Medicines USA
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adds 400 mg IV every six weeks with platinum and fluoropyrimidine chemotherapy for first-line unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma in adults with tumor PD-L1 expression of at least 1.
LAMPGEN ANALYSIS
Why it matters
The six-week checkpoint schedule is an additional option for this established first-line combination.
What research teams should watch
Reconcile the separate checkpoint and chemotherapy schedules so cycle timing remains clear for patients and pharmacy.
PRIMARY RECORDS